Highlight
- Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse event (irAE)-induced treatment interruption in classical Hodgkin lymphoma (cHL) is feasible and generally safe.
- Progression-free survival (PFS) and duration of response (DOR) were not significantly different between patients who underwent ICI rechallenge and those who did not within the same treatment line.
- Recurrent irAEs occurred in 20% of rechallenged patients, with recurrence of the same irAE in only 7%, indicating manageable safety signals.
- In patients rechallenged at subsequent therapy lines, median PFS varied notably depending on prior response, highlighting the influence of disease status on outcomes.
Specialty calculators
For clinical reference; use professional judgment.
